Related Experiment Video

Updated: Jun 10, 2026

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
08:08

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation

Published on: July 8, 2011

Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN

Jin Hee Kim1, Tae Heung Kang, Kyung Hee Noh

  • 1Laboratory of Infection and Immunology, Graduate School of Medicine, Korea University, Seoul, South Korea.

Immunology Letters
|August 24, 2010
PubMed

Insights

This study enhances dendritic cell (DC) cancer vaccines by using small interfering RNA (siRNA) to target PTEN, improving DC survival and anti-tumor immune responses for better cancer immunotherapy.

Area of Science:

  • Immunology
  • Cancer Research
  • Molecular Biology

Background:

  • Dendritic cell (DC)-based cancer vaccines are crucial for anti-tumor immunity but limited by short DC lifespan.
  • The PI3K/AKT pathway, particularly AKT/protein kinase B (PKB), is vital for DC activation and survival.
  • PTEN is a key negative regulator of the PI3K/AKT pathway.

Purpose of the Study:

  • To enhance the potency and clinical efficacy of DC cancer vaccines.
  • To investigate the role of PTEN down-regulation in DC function and survival.
  • To explore the potential of siRNA-mediated PTEN inhibition for improved cancer immunotherapy.

Main Methods:

  • Utilized small interfering RNA (siRNA) targeting PTEN (phosphatase and tensin homologue) in DCs.
  • Analyzed AKT-dependent DC maturation, co-stimulatory molecule expression, and CCR7 up-regulation.
  • Assessed in vitro T cell activation, in vivo lymph node migration, DC survival, and anti-tumor effects in vaccinated mice.

Main Results:

  • PTEN down-regulation via siRNA led to AKT-dependent DC maturation and increased co-stimulatory molecule and CCR7 expression.
  • PTEN-silenced DCs (DC/siPTEN) showed enhanced in vitro T cell activation and in vivo migration.
  • DC/siPTEN exhibited improved survival against apoptotic stimuli and generated stronger anti-tumor effects in vivo.

Conclusions:

  • Targeting the PI3K/AKT pathway with siRNA against PTEN significantly enhances DC vaccine efficacy.
  • PTEN inhibition boosts DC maturation, survival, and anti-tumor immune responses.
  • This strategy offers a promising approach for developing more effective DC-based cancer vaccines.

More Related Videos

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro06:12

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Published on: March 7, 2022

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...